Bioniq, a London, UK-based provider of personalized supplements based on blood biomarker data, raised $15M in Series B funding.
The round was led by HV Capital and Unbound.
The company, which is valued at $75M, intends to use the funds to further expand its global market share.
Led by CEO Vadim Fedotov, Bioniq specializes in offering AI-driven personalized supplements based on blood test data. After conducting years of testing, it has developed a proprietary biochemical database with blood test data from customers across 5 continents. Shipping globally, the company has created formulas for over 100,000 users that incorporate components and dosages to each individual’s nutrient deficiencies, as identified through their blood results.
Commenting on the news, Vadim Fedotov said: “Everyone’s health journey is unique and fluid. Customers need advanced, adaptable products that provide evolving support for personal health goals. Our AI-driven approach and extensive biochemical database allow us to create customized supplements that provide quantifiable results and cater to individuals’ specific needs. Beyond meeting consumer demand, we’re setting a new standard in the industry by making the process and results transparent to the users.”
FinSMEs
16/07/2024